Results 221 to 230 of about 4,559,471 (378)

Management of Cardiovascular Health Issues in Turner Syndrome: Expert Insights and Expanded Recommendations From the 2024 Guideline Development Team

open access: yesAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT Turner syndrome (TS) is frequently complicated by congenital heart disease (CHD). While left‐sided lesions such as bicuspid aortic valve (BAV) and coarctation of the aorta are the most common structural heart lesions in TS, other anomalies, such as aortic arch malformations, hypoplastic left heart syndrome (HLHS), persistent left superior vena
Katya de Groote   +9 more
wiley   +1 more source

A Case Study of the Thermal Environment in the Airport Terminal Building under Natural Ventilation [PDF]

open access: gold, 2009
Qinglin Meng   +6 more
openalex   +1 more source

The Diagnosis That Arrived Decades Late: Living Without and Then With Myhre Syndrome

open access: yesAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT Myhre syndrome (MIM #139210) is a rare multisystem disorder first described in 1981, characterized by short stature, neurodevelopmental delay, joint contractures, and cardiopulmonary complications. Its molecular basis, recurrent pathogenic variants in SMAD4, was not discovered until 2011. This narrative is based on a review of medical records,
Abdallah F. Elias
wiley   +1 more source

Intratympanic dexamethasone microcrystals/lidocaine‐loaded PLGA non‐spherical microparticles for local drug delivery to the inner ear

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Optimized lidocaine‐loaded PLGA non‐spherical particles (LPNMs) and dexamethasone microcrystals (DEX MCs) were prepared. They were then mixed in sodium hyaluronate solution to obtain a co‐delivery system, administrated in guinea pigs to evaluate the pharmacokinetics and biocompatibility of the system.
Dongcheng Wang   +7 more
wiley   +1 more source

New approaches to treating chronic obstructive pulmonary disease with Colla corii asini

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Colla corii asini improves chronic obstructive pulmonary disease (COPD) treatment through anti‐inflammatory, antioxidant, immune‐modulatory, and lung‐nourishing effects, addressing current therapeutic challenges via multitarget mechanisms. Abstract Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death and disability ...
Wenchao Zhang   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy